Evidence map›Paper›PMID 33389336›Full record

ArticleClinical & experimental metastasis2021

Modeling breast cancer survival and metastasis rates from moderate-sized clinical data.

Esha Maiti

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Esha MaitiData Science, Chief Data Office, Kaiser Permanente, Pleasanton, CA, 94588, USA. eshmait@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting time-dependent survival probability of a breast cancer patient using information such as primary tumor size, grade, node spread status, and patient age at the time of surgery can be of immense help in managing life expectations and strategizing postoperative treatment. However, for moderate-sized clinical datasets the application of standard Kaplan-Meier theory to determine survival probability as a function of multiple cofactors can become challenging when continuous variables like tumor diameter and survival time are segmented into a large number of narrow intervals, a problem commonly termed the curse of dimensionality. We circumvent this problem by modeling the patient-to-patient distribution of primary tumor diameter with a realistic, right-skewed function, and then matching the diameter-marginalized survival with the mean Kaplan-Meier survival for the data. We apply this procedure on a recent clinical data from 1875 breast cancer patients and develop parameters that can be readily used to estimate post-surgery survival for an arbitrary time length. Finally, we show that the observed fraction of node-positive patients can be quantitatively explained within a simple tumor growth and metastasis framework. Employing two different tumor growth models from the literature (i.e., Gompertz and logistic growth models), we utilize the observed fraction-node-positive data to determine metastasis rates from the surface of a primary tumor and its patient-to-patient distribution.

Indexed as

Models, StatisticalAgedBreast NeoplasmsClinical Trials as TopicFemaleFollow-Up StudiesHumansMiddle AgedPrognosisSurvival RateBreast cancerKaplan–MeierMetastasis rateSurvivalTumor growth

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.